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Abstract
Aim To ascertain the quantity and nature of gifts and
items provided by the pharmaceutical industry in
Australia to medical specialists and to consider whether
these are appropriate in terms of justifiable ethical
standards, empirical research and views expressed in the
literature.
Design and Setting Fifty-one medical Sydney special-
ists were asked to collect all gifts, offers, invitations,
and items received from pharmaceutical companies in
an eight-week period.
Main Outcome Measures The items received were
categorised as promotional/educational, drug samples,
clinical practice aids, office gifts, personal gifts, and
invitations; and were analysed in relation to the
pharmaceutical industry Code of Conduct.
Results A large number (mean=42/participant) and
wide range of gifts and items were received. These
included promotional/educational items (mean=21),
drug samples (mean=8), office gifts (mean=5) and
personal gifts (mean=1), clinical aids (mean=3), and
invitations (mean=3) to meals, meetings, and confer-
ences. Most gifts and items complied with the Code
with a few breaches including offers of entertainment
(sporting event and cabaret), items of high monetary
value (in competitions with prizes unrelated to
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medicine), unbranded gifts, and promotional docu-
ments presented as journal articles.
Conclusions Medical specialists received many gifts
and items from pharmaceutical companies and a few
that infringed the Code current at the time of the study.
The findings were considered in the light of changes that
have since been made to the industry Code of Conduct
and professional medical guidelines on ethical relation-
ships between physicians and the industry. In large
measure, these changes are supported although some
suggestions are made for stricter standards.
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Introduction
This was a study of gifts and other items received by
medical specialists from pharmaceutical companies. It
was conducted in Sydney, Australia, and was based
on medical specialists as they are regarded by the
industry as opinion leaders and have an extensive role
in industry-sponsored education of junior doctors and
general practitioners [22, 25]. The study is a part of a
larger project that aims to establish whether the
relationship between the pharmaceutical industry, the
medical profession, and medical practitioners is
appropriate in terms of justifiable ethical standards,
empirical research and social perspectives. A number
of reports arising from the project have been published
to date [6, 10, 11, 13, 17].
Background
Pharmaceutical companies give gifts to doctors as a part
of promoting and marketing their products [14]. There
are concerns about the effect of these gifts however.
Although many doctors deny the potential for gifts to
influence their judgment [12, 30], it has been found
that medical practitioners’ attitudes to the pharmaceu-
tical industry, their knowledge about pharmaceutical
products, and prescribing behaviour are influenced by
industry promotion and gift-giving [3–5, 7, 8, 12, 21,
29–31]. Katz et al. claim that all gifts, both large and
small, create a social obligation to respond and the
only way for a medical practi-tioner to reciprocate is to
support the company’s products [12].
Nevertheless, gifts, offers, and promotional items,
remain significant elements in the relationship between
the pharmaceutical industry and the medical profession
[3, 21, 23–25]. These include items for the office (pens
and pads), promotional items, drug samples and infor-
mation, personal gifts, invitations to various events, and
travel support and accommodation to attend national
and international conferences and other meetings.
Australian codes and ethical guidelines, relevant to
medical practitioners receiving gifts, items and other
support from pharmaceutical companies, are contained
in the Australian Medical Association (AMA) guide-
lines [26], the Royal Australasian College of Physi-
cian’s (RACP) Guidelines [28], and the industry Code
of Conduct [20]. Of these, the Medicines Australia
(pharmaceutical industry) Code [20] and the RACP
Guidelines [28] are the most important and both have
been recently updated. This study was conducted in
2002 when a previous industry Code of Conduct [1]
and the earlier RACP Guidelines [27] were in effect
and these earlier standards are considered in this
paper in relation to what was acceptable at the time.
The general principles embodied in the Code [20]
and Guidelines [26, 28] are that any gift or benefit
from a pharmaceutical company should leave a
physician’s judgment “unimpaired” [28]; that gifts
that could influence prescribing of drugs should not
be accepted [26]; and physicians should avoid any
appearance of impropriety in accepting gifts [26, 28].
Gifts, items and other support should only be accep-
ted if they are relevant to the practice of medicine and
of benefit to patients [28]. The Medicines Australia
Code limits gifts to brand-name reminders of token
value [20] whereas the recently amended RACP
Guidelines recommend rejecting all gifts including
‘items of trivial value such as pens or message pads’
and state that ‘service-oriented items’ are only
acceptable on ‘rare occasions’ such as where they
‘are not otherwise readily available’ [28].
The industry Code, and the AMA and RACP
Guidelines allow food and refreshment in association
with educational meetings, conferences, or company
events provided it is not lavish [28] or extravagant [20],
and secondary to the educational purpose of the
meeting [26, 28]. The industry Code allows Companies
to provide financial assistance to doctors to attend
meetings [20] although the RACP Guidelines recom-
mend that support should only be offered to speakers
and chairpersons and that any support be distributed by
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the organisers of meetings not directly by companies
[28]. Entertainment in association with professional
meetings is no longer acceptable within the Medicines
Australia Code [20] and is discouraged by the RACP
Guidelines [28] and gifts of tickets to entertainment
events are no longer acceptable [20, 28].
Both the recent Code and the RACP Guidelines take
a more restrictive stance on company representatives
supplying drug samples to doctors. The newMedicines
Australia Code requires that any drug samples only be
supplied where there is a written and signed request
from a health professional [20]. The RACP Guidelines
state that a ‘sample or a free supply of a drug’ is a
‘marketing exercise’ in most circumstances and that
accepting drug samples ‘is usually inappropriate’ [28].
They also recommend that doctors exercise caution in
dealing with pharmaceutical company representatives
and promotional materials as contact with them ‘erodes
physicians’ ability to identify wrong claims, increases
non-rational prescribing and results in acceptance of
commercial rather than scientific views.’ The Guide-
lines recommend critical evaluation of all promotional
material because it is ‘often biased, incomplete or
unsupported by evidence and may promote unap-
proved uses’ [28].
Aim of the Study
As a part of the broader goal of the project, in de-
termining whether the relationship between the
pharmaceutical industry and medical practitioners is
appropriate, we wanted to know what doctors are
actually given by pharmaceutical companies. Most
studies are based on surveys and self-report, mainly in
the USA. There have been few observational studies of
gifts and items actually received by doctors – an
exception being a study of items carried in doctors’
pockets [24]. The aim of this study was to determine
the number of gifts actually received by doctors
within a set period. To do this we sought to ascertain
all gifts, offers, invitations, and items received by 51
medical specialists in the Sydney region from phar-
maceutical companies in an eight-week period at the
end of 2002.
Materials and Methods
The study methods were approved by the Human
Research Ethics Committee of the University of New
South Wales. A list of 814 specialist medical practi-
tioners with practice addresses within the Sydney
metropolitan region was supplied by the Medical
Directory of Australia (AMPCo Pty Ltd). This included
the major clinical subspecialties (listed in Table 1) with
the exception of surgeons, who were not included
because they have little responsibility for long-term
prescribing. Of these, 400 specialists were randomly
selected and a letter of invitation was sent which asked
them to return a reply paid card if they were willing to
be contacted further about the study. No reminders
were sent to non-responders. The invitation letter
outlined the study methods, requiring them to collect
all materials received from pharmaceutical companies
(excluding email correspondence) during a continuous
eight-week period in late 2002. All participants were
provided with labelled archive boxes (hereafter referred
to as ‘bins’). A member of the research team (Research
Assistant) conducted all telephone and in-person inter-
views. During an introductory in-person interview, the
project was discussed, and the support of an appropri-
ate member of the specialist’s staff (receptionist, or
practice manager) was enlisted. Participants were
contacted by telephone mid-way through the study to
discuss progress. Bins were collected at the end of
eight weeks and participants completed an exit
Table 1 Numbers of specialists included in the study.















Intensive care physician 1
Emergency medicine physician 1
Reproductive medicine physician 1
Total 51
aMember of a ‘high value’ prescribing specialty as per
Pharmaceutical Benefits Scheme expenditure figures.
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interview in person or completed a questionnaire (if
unavailable for an interview), which asked for an
estimate of their success rate in depositing received
items in the bin, whether there were other offers of
gifts or items that were not captured, and their
experience in conducting the study.
We analysed the data to determine whether gifts and
drug samples were offered preferentially to members
of ‘high value’ prescribing specialties, based on annual
Pharmaceutical Benefits Scheme (PBS) reports of drug
classes ranking by total cost to Government (during
2003) which define ‘high value’ prescribers as:
psychiatrists; cardiologists; gastroenterologists; respi-
ratory physicians; rheumatologists; infectious disease
physicians; and oncologists. The associations between
‘high value’ prescribers and numbers of gifts (includ-
ing number and type of drug samples) were quantified
by odds ratios and 95% confidence intervals (calculat-
ed by the exact method) [16]. Bin collections were
reviewed to see if any items breached the relevant
sections of the Code of Conduct [1].
Results
Response Rates
One hundred and forty six medical specialists
responded (response rate of 36.5%) of whom 102
were willing to take part in the study (25.5%). Of
those: five did not meet the study criteria (two were
not available during the study period, and three were
not in active specialist medical practice). Of those
who agreed to participate we selected 51 specialists,
attempting to ensure representation of all relevant
medical specialties.
Respondent Characteristics
Forty-two males and nine females participated, and all
completed eight weeks of the study. The group
comprised specialists from different specialties (see
Table 1). On average, respondents divided their time
equally between private and salaried practice (48 and
49%, respectively). They spent 63% of their time in
patient care, 15% in administration, 9% research, 7%
teaching, and 6% ‘other’. Sixty-one percent of special-
ists saw 0–10 patients per day, 31% saw 11–20, 8%
saw 21–30, 2% saw more than 30. Eight percent of
specialists wrote no scripts, 76% prescribed 1–20 script
items per day, 12% 21–50 items, and 4% more than 50.
The mean number of pharmaceutical representatives
seen during the eight-week study period was 7.4 (range
0–25). In both mid-point and exit interviews, participants
reported that the study was relatively non-obtrusive
and that the only difficulty was in remembering to put
items in the designated ‘bin’. In exit interviews par-
ticipants estimated their success in depositing items,
given or sent to them, in the ‘bin’ as between 80 and
100% (mean 93%).
Bin Collections
The study was conducted between mid-June and mid-
December in 2002. The 51 respondents collected a total
of 2,117 items (mean 41.5 items/participant; median
29; range 0–174) over eight weeks. Figure 1 shows the
distribution of total numbers of items collected by
participants and Fig. 2 displays the mean number of
promotional/educational items, drug samples, office
gifts, invitations, clinical practice aids, and personal
gifts received.
Details of Gifts
Promotional/educational items (n=1052, mean=20.6/
participant) were received by 49 respondents (mean=
21.5, range 1–86). These included: promotional
brochures (mean=9.3/participant), product informa-
tion/consumer medicine information (mean=3.6/par-
ticipant), and published paper reprints (mean=2.4/
participant). Some consisted of offers (mean=2.4/
participant), which on return of a card promised: drug
samples (total n=64), textbook, CD-ROMs, access to
websites for information (total n=2), sphygmoma-
nometer, laser pointer, golf balls, clock, jar of sweets,
jar of lollypops, and others. There were ‘chance-to-
win’ competitions (mean=1.0/participant) all of
which required a response from the doctor, such as
providing words to describe a drug, and offered prizes
including: conference registration, flights and accom-
modation for a conference in USA; leather doctor’s
case (total n=7); pocket PC (total n=6); magazine
subscription (total n=4); digital camera (total n=3);
textbook (total n=3); and branded golf balls. Less
common promotional items (mean<1/participant)
included: sponsored newsletters, sponsored confer-
ence proceedings, journal issues, unpublished studies,
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audiotape/CDs, textbooks, published conference pro-
ceedings, sponsored practice guidelines and published
practice guidelines.
Drug sample packs (n=420 packs, mean=8.2/
participant) were received by 17 specialists (mean=24.7,
range 1–104). Thirty-five percent of samples were drugs
for gastrointestinal diseases (mainly acid pump inhib-
itors); 20% were drugs for psychiatric disorders (mainly
anti-depressants); 19% were drugs for cardiovascular
disorders (mainly angiotensin receptor antagonists);
14% were dermatological products; the remaining
samples (12%) were for musculoskeletal endocrine and
allergic disorders. Of these sample packs 328 of 420
(78%) were from the ‘high value’ drug classes (OR 4.7;
95% CI 2.5, 9.0). Fewer than half of the participants (22
of 51, 43%) came from ‘high value’ prescribing
specialties (see above) but they were over-represented
in the group that received drug samples during the study
period (10 of 17) although the difference was not
statistically significant (OR 2.6; 95% CI 0.68, 10.3).
Office gifts (n=258 items, mean=5.1/participant) were
received by 34 specialists (mean=7.6, range 1–24). These
included pens (mean=2.1/participant) and the following
items (<1 item/participant): notepads, Post-it© labels, mug,
paper carry bag, fridge magnets, diary, laser pointers,
cardholder. All were branded with the name of a drug (as
was required) [1].
Invitations (n=174, mean=3.2) were received by 36
specialists (mean=4.8, range 1–15); with 89 dinner
invitations received by 31 respondents (mean=2.9,
range 1–9); and 48 invitations to breakfast received by
17 respondents (mean=2.8, range 1–10). Dinner
invitations included expensive restaurants (13 invita-
tions to highest-rate $$$$-category restaurants (http://
sydney.citysearch.com.au/section/food_wine/, last
accessed August, 2005; http://www.eatability.com.au/,
last accessed August, 2005) and 22 to restaurants in
five-star hotels); many including entertainment (one
such event being a recital by “Australia’s most
acclaimed classical pianist”). One dinner invitation
included a competition with a travel grant to an
international conference of the winner’s choice. One
participant received an invitation to an international
conference with a business class airfare, accommoda-
tion, food, and registration (offered to the physician or
member of his/her department). There were 13
invitations to weekend meetings with accommodation;
most with travel, including: conferences/symposia/
educational (n=9); events promoting a specific drug
(n=2); company advisory board (n=1); and not
specified (n=1). Some invitations to weekend meetings
included partner (n=8) and some did not (n=5). Of the
eight invitations to weekend meetings that included
partners and children (n=4), all but one required
Figure 1 Total numbers of items collected by participants.
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contributions to the costs of partners (and children) in
varying amounts for partner/child ($100–245/partner
and $35–65/child). Two respondents received invita-
tions to a ‘post-graduate weekend’ with accommoda-
tion, dinner and cabaret starring leading popular singer
Tina Arena.
Clinical practice aids (n=148 items, mean=2.9
items/participant) were received by 29 specialists
(mean=5.1, range 0–12). These included: clinical
equipment (stethoscope, sphygmomanometer, glucose
test strips); patient/carer materials (mostly booklets);
diagrams/models; and dose/drug interaction charts.
Personal gifts (n=65 mean=1.3 items/participant)
were received by 26 specialists (mean=2.5, range 0–
15). These included many branded items (n=55)
such as: coffee plungers; shaving brushes; bottle
openers; key rings with small flashlight; umbrellas;
collapsible golf-putter set (including ball and wooden
‘hole’); book on wines (n=2); clocks; and red
‘Viagra’ boxer shorts. Unbranded personal gifts (n=
10) included pocketknife; wine; chocolates; small tea
chest; lamp; and tickets to a football (AFL) game with
partner, including box seats, drinks and food; and two
tickets to a cabaret.
There was no significant difference between the
numbers of gifts received from the pharmaceutical
industry by members of ‘high value’ prescribing
specialties and others.
Compliance with the Industry Code of Conduct
We analysed the gifts received to consider which were
in breach of the Code of Conduct of the Australian
Pharmaceutical Manufacturers Association [1, the
extant Code at the time of the study]. We took this
Code as the benchmark, rather than the RACP
guidelines [27], because pharmaceutical companies
and their representatives are required to adhere to this
Code; any breach of the Code can be the subject of a
complaint which is investigated and reported on by a
monitoring committee; and because breaches of this
Code, unlike breaches of the Guidelines, could have
led to direct sanctions [1].
We found that the following gifts breached the
Code of Conduct [1]: tickets to entertainment events
(including two tickets to the cabaret and two to an
AFL football game) and dinner with entertainment
by leading Australian performers. The Code stated,
Figure 2 Mean number of items collected by participants according to category of item received.
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‘[e]ntertainment or other hospitality offered to health-
care professionals should be appropriate, secondary to
the educational content and in proportion to the oc-
casion’ [1]. A number (n=33) of the ‘chance-to-win’
competitions included prizes that did not meet the
requirement of being ‘directly relevant to the practice
of medicine or pharmacy’ and of ‘low monetary
value.’ These included: digital cameras; pocket PCs;
and doctors’ leather cases (which, although relevant
to medicine, are expensive). However it is acknowl-
edged that a doctors’ leather case may now be
permissible under supplementary guidelines to the
subsequent Code, which allow competition prizes of a
value up to $500 [19]. The same Guidelines would
also allow a pocket PC (or PDA) with MIMS or
medical software [19]. Whilst the majority of personal
gifts received by participants were consistent with the
Code, some (such as a book on Australian wine) were
of more than token value or were unbranded (e.g.,
soft toy, pocketknife). Two promotional documents,
presented in the form of academic journal articles,
proved on closer inspection to be company reports, in
contravention of the Code [1].
Edition 14 of the Medicines Australia Code of
Conduct [18] came into effect in January 2003
(subsequent to this study) with tighter restrictions
including: provisions that companies should not pay
the costs of family members of doctors attending
meetings; provisions that ruled out entertainment; and
further requirements that any hospitality offered should
be simple, modest, and secondary to the educational
content of a meeting [19]. The following offers
received by participants in our study would have been
excluded by the new rules: one night in 4.5 star hotel
with partner wholly subsidised (n=1); and invitations
to dinner at expensive restaurants, five-star hotels, and
restaurants where entertainment was provided (n=35).
Discussion
A considerable volume and wide range of items, gifts,
and invitations were received by medical specialists from
the pharmaceutical industry over an eight-week period.
The larger portion consisted of promotional/educational
items, and drug samples. The drug samples offered were
predominantly from ‘high value’ drug classes, indicating
that companies are more active in promoting drugs with
more profitable returns. Participants received 21 promo-
tional/educational items on average. A few of these (up to
four on average)may have been required by the Code (for
example: product information was to accompany bro-
chures promoting a ‘new chemical entity’ [1]) but even
so this is a large number. Participants also received
clinical aids, office gifts and invitations to dinner or
breakfast associated with meetings. A small number
received invitations to weekend meetings or events,
some with their partners. Most gifts and invitations
complied with the then current Code of Conduct. Those
that breached the Code included invitations to entertain-
ment or sporting events, items of high monetary value
including ‘chance-to-win’ competitions with prizes of
significant value, prizes unrelated to the practice of
medicine, personal gifts of more than token value, and
company promotional reports presented as academic
journal articles. It is noted that offers of dinner at
expensive restaurants, the provision of entertainment
with dinner, and accommodation for a doctor’s partner,
whilst not specifically excluded by the then current
Code [1], would have contravened the subsequent 2003
Code [18].
Some qualifications to these findings are as follows.
A positive response rate of 25.5% from medical
specialists is not unusual in a study that relies on
posted responses to requests sent by mail. It is too low,
however, to assume that our participants were repre-
sentative of all Sydney-based medical specialists or the
larger population of medical specialists throughout
Australia. Given the geographical and other restraints
on this study, achieving a more representative sample
was not possible. Whilst we included at least one
specialist from all the major specialties (other than
surgery for reasons given above) the numbers were not
sufficient within each group to make meaningful
comparisons between the specialty groups. Nor are
these results indicative of the number of gifts and other
items received by general practitioners.
A further qualification is to do with the timing of
the study. Some participants commented (during exit
interviews) that fewer gifts and invitations had been
offered in this period as a result of criticism of
companies in the media at the time, and an expected
tightening of the standards in the 2003 Code of
Conduct [18]. It is also possible that not all gifts were
‘captured,’ although participants estimated that they
had deposited between 80 and 100% (average 93%)
of relevant items in the bins.
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Nevertheless, this is one of the few studies to date
to publish observational data on the number of gifts
and other items received by physicians from pharma-
ceutical companies. The number of gifts and other
items received by our participants in a relatively brief
(eight-week) collection period was considerable.
Based on a direct extrapolation from these figures
(to a 48 week year), a medical specialist, on average,
could have then expected to receive around 230 items,
comprising 125 promotional/educational items (in-
cluding 14 offers of gifts and six competitions on
return of a card); 50 drug sample packs; 30 office
gifts; 20 invitations (including 11 invitations to dinner
and one weekend meeting at a four or five star hotel);
17 clinical practice aids; and eight personal gifts.
These findings give some indication of the extent to
which the industry Code was effective in maintaining
limits on the giving of gifts to medical practitioners. By
and large, most gifts were within the required limits,
although there were significant breaches. Since 2002,
the Code has been amended (in 2003 [18] and in 2006
[20]). It may be reasonable to assume that most gifts,
invitations, and items offered to medical practitioners
will conform to the stricter limitations in the current
Code. However it can be expected that, without
evidence of any other significant change in the
industry, company representatives will continue to test
the limits and some will go beyond them. It can also be
anticipated that, with stricter limits, companies will
become more inventive in finding alternative means for
promotion. There are already indications that pharma-
ceutical companies have shifted their promotional
efforts. They now give greater emphasis to indirect
promotion by funding continuing medical education
for medical practitioners [2].
The broader context of this study is that profes-
sional bodies and pharmaceutical companies have
responded to accusations of professional or commer-
cial impropriety by developing codes of ethics to
govern the relationship between industry and the
profession in order to restore and maintain public
confidence. Competition within the pharmaceutical
industry for market share is the principal driver for
promotional activity including the giving of gifts in
addition to other items. The aim of pharmaceutical
companies is to influence doctors’ prescribing behav-
iour and gain a competitive advantage. The result of
these activities was that pharmaceutical company
largesse became the norm. This led to a culture in
which gifts were offered because they were expected,
accepted, and desired by medical practitioners. In that
environment, ethical limits were stretched and, in
some cases, breached. We note however that the most
recent industry Code [20] and professional Guidelines
[28] are more restrictive in regards to what gifts and
sponsorship companies can offer, and more conserva-
tive in the recommendations to physicians as to what
they can appropriately receive. These documents may
aid in bringing about a change in the culture.
This study is part of a larger project that aims to
establish whether the relationship between the phar-
maceutical industry, the medical profession, and
medical practitioners is appropriate in terms of
justifiable ethical standards, empirical research and
social perspectives. The aspect of the relationship
focussed on in this study is the giving of gifts and
other items. We take the view that, while some items
given may be judged to be appropriate, there were
many that are difficult to justify.
We are persuaded by Katz et al., that gifts,
including those of negligible value, can influence
the behaviour of doctors and that ‘policies that
determine the acceptability of a gift according to its
size are unsound’ [12]. We also note that the
Medicines Australia Code now limits gifts to ‘brand
name reminders’ of ‘token value’ that are ‘relevant to
the working environment’ [20]. However these
provisions do not take sufficient account of the
‘power of gift-giving, both large and small’ on
medical practitioners. Katz et al. take the view that
gifts are ‘marketing wares’ and that ‘all gifts, large
and small,’ are not appropriate and should be
prohibited [12]. The RACP Guidelines [28] observe
that ‘even items of small value which superficially
appear to be innocuous are intended to sway doctors’
judgments’ and may create an impression at least that
the doctor has not kept an appropriate distance from
the industry. The Guidelines recommend that all gifts
including ‘items of trivial value such as pens or
message pads’ be rejected [28]. We support that
recommendation and suggest that the RACP standard
should be adopted by the industry so that companies
refrain from giving gifts of all kinds, including those
given as brand name reminders and gifts given as the
result of a “competition.”
We found that physicians receive a great deal of
promotional material. Whilst we accept the concern of
the RACP that this material can be biased, incomplete,
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and unsupported by evidence [28], we agree that it is
unrealistic to prohibit its use [15]. We therefore support
both the Medicines Australia approach of requiring that
this material meet certain standards [20], and the
RACP strategy of encouraging doctors to critically
evaluate all promotional material [28].
Drug sample packs were received by a large num-
ber of the participants in our study. Since this study
was conducted both the industry Code [20] and the
professional Guidelines [28] have become more
cautious with regard to drug samples. The Medicines
Australia Code now requires that doctors make a
written request for drug samples [20] while the RACP
Guidelines state that it is ‘usually inappropriate’ to
accept drug samples because the purpose for giving
samples is to ‘accustom the clinician to prescribing a
particular product’ and ‘to establish a cohort of
patients on long-term treatment with a particular drug’
[9, 28]. The drugs most commonly given to physicians
in our sample were from ‘high value’ drug classes.
This supports a view, expressed by Grove et al., that
drug samples are a ‘major component of the promo-
tional effort’ and a ‘critical driver in the promotion
and adoption of new products’ [9]. Many concerns
have been expressed about potential negative effects
of drug samples including: influencing prescriber
behaviour; patient safety; and adding to the cost to
of pharmaceuticals [9]. Grove et al. conclude that
research into these effects is lacking and is needed to
underpin policies on the use of drug samples [9].
Nevertheless we take the view that the potential for
bias and for harm to patients, and an apparent upward
pressure on the cost of drugs, are consequences that
are sufficiently serious to justify taking a conservative
approach. We therefore support the RACP recommen-
dation that doctors should not accept drug samples
‘apart from exceptional circumstances’ [28] and
suggest that further reflection is required to define
the ‘exceptional circumstances’ in which the accep-
tance of drug samples might be appropriate so that the
giving of drug samples can be restricted to just those
circumstances. A similar approach has been proposed
by the RACP in relation to practice aids, whereby gifts
of ‘service-oriented items’ are only appropriate where
they ‘are not otherwise readily available’ [28].
There was one offer of business class international
travel received from a pharmaceutical company by a
physician in our study. In our view this is an
inappropriate gift unless it is received indirectly from
the organisers of a conference or meeting and we
support the RACP restrictions on travel and attendance
costs for attending meetings [28, 17]. Many of our
study participants received invitations to meals paid for
by pharmaceutical companies in association with
meetings or educational events. We suggest that
caution is needed in giving and receiving of food and
hospitality. We note that both the current industry Code
[20] and RACP Guidelines [28] allow hospitality in
conjunction with a meeting (when there is a significant
educational content) provided it is not extravagant [20]
or lavish [28]. We found that there were at least 37
meals offered in restaurants with the top ratings or five-
star hotels. Given that individuals judge standards
according to their own values we suggest that it could
always be argued that such offerings were not
extravagant or lavish and were ‘consistent with the
professional standing’ [20] of the physicians. We
suggest that this language is too permissive and
recommend to the RACP and Medicines Australia that
they re-consider those provisions and use the language
of the previous industry Code that restricted hospitality
to meals that are ‘simple’ and ‘modest’ [18].
We take heart from the fact that the pharmaceutical
industry body (Medicines Australia) and a predominant
specialist college (RACP) are active in reviewing the
relationship between the pharmaceutical industry, the
medical profession, and medical practitioners and that
both bodies appear to be alert to community concerns,
empirical research, and social perspectives on the
appropriateness of gifts and items given by pharmaceu-
tical companies and received by medical practitioners.
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